人乳头瘤病毒疫苗的概况及重组三价人乳头瘤病毒疫苗的研发

Overview of Human Papillomavirus Vaccine and Development of Recombinant Trivalent Human Papillomavirus Vaccine

人乳头瘤病毒(HPV)的持续感染是诱发宫颈癌的主要原因,通过接种HPV疫苗,可有效降低HPV感染的风险,继而降低宫颈癌的患病概率。本文阐述了HPV的分型、分子流行病学研究以及国内已上市HPV疫苗情况,介绍了本公司自主研发的重组三价HPV疫苗及其技术创新性,并开展了免疫原性研究。结果表明,重组三价HPV疫苗可使小鼠和大鼠产生高滴度、持久性强的特异性中和抗体,并且免疫效果与默沙东公司研制的Gardasil疫苗相当。

Persistent human papillomavirus(HPV)infection is the main cause of cervical cancer induction.HPV vaccination effectively reduces the risk of HPV infection,thereby decreasing the probability of cervical cancer.This article describes HPV typing,molecular epidemiology,and the current market status of HPV in China.Additionally,it introduces the research and development and technological innovation of a recombinant trivalent HPV vaccine independently developed by our company.Immunogenicity research has been conducted,revealing that recombinant trivalent HPV vaccine can induce high-titer and long-lasting specific neutralizing antibodies in mice and rats.The immune effect is comparable to that of Gardasil,a vaccine developed by Merck.